Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
United Therapeutics Corporation is a biotechnology business based in the US. United Therapeutics Corporation shares (UTHR) are listed on the NASDAQ and all prices are listed in US Dollars. United Therapeutics Corporation employs 965 staff and has a trailing 12-month revenue of around $1.8 billion.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Active traders
| Latest market close | $205.89 |
|---|---|
| 52-week range | $158.38 - $245.48 |
| 50-day moving average | $222.27 |
| 200-day moving average | $205.67 |
| Wall St. target price | $248.56 |
| PE ratio | 15.7407 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $13.19 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $205.89 from 2022-09-27
| 1 week (2022-09-21) | 0.16% |
|---|---|
| 1 month (2022-08-26) | -4.37% |
| 3 months (2022-06-28) | -12.02% |
| 6 months (2022-03-25) | 17.76% |
| 1 year (2021-09-28) | 9.71% |
|---|---|
| 2 years (2020-09-28) | 102.83% |
| 3 years (2019-09-27) | 154.69% |
| 5 years (2017-09-28) | 73.37% |
Valuing United Therapeutics Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of United Therapeutics Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
United Therapeutics Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 16x. In other words, United Therapeutics Corporation shares trade at around 16x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
United Therapeutics Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.8291. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into United Therapeutics Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
United Therapeutics Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $939.1 million.
The EBITDA is a measure of a United Therapeutics Corporation's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $1.8 billion |
|---|---|
| Operating margin TTM | 49.7% |
| Gross profit TTM | $1.6 billion |
| Return on assets TTM | 10.7% |
| Return on equity TTM | 15.85% |
| Profit margin | 35.27% |
| Book value | $94.93 |
| Market capitalisation | $9.5 billion |
TTM: trailing 12 months
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like United Therapeutics Corporation.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 35.51
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and United Therapeutics Corporation's overall score of 35.51 (as at 12/31/2018) is nothing to write home about – landing it in it in the 54th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like United Therapeutics Corporation is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 6.16/100
United Therapeutics Corporation's environmental score of 6.16 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that United Therapeutics Corporation is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 24.94/100
United Therapeutics Corporation's social score of 24.94 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that United Therapeutics Corporation is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 17.41/100
United Therapeutics Corporation's governance score puts it squarely in the 9th percentile of companies rated in the same sector. That could suggest that United Therapeutics Corporation is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. United Therapeutics Corporation scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that United Therapeutics Corporation has, for the most part, managed to keep its nose clean.
United Therapeutics Corporation was last rated for ESG on: 2019-01-01.
| Total ESG score | 35.51 |
|---|---|
| Total ESG percentile | 53.55 |
| Environmental score | 6.16 |
| Environmental score percentile | 9 |
| Social score | 24.94 |
| Social score percentile | 9 |
| Governance score | 17.41 |
| Governance score percentile | 9 |
| Level of controversy | 2 |
We're not expecting United Therapeutics Corporation to pay a dividend over the next 12 months.
United Therapeutics Corporation's shares were split on a 2:1 basis on 22 September 2009. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your United Therapeutics Corporation shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for United Therapeutics Corporation shares which in turn could have impacted United Therapeutics Corporation's share price.
Over the last 12 months, United Therapeutics Corporation's shares have ranged in value from as little as $158.38 up to $245.48. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while United Therapeutics Corporation's is 0.5358. This would suggest that United Therapeutics Corporation's shares are less volatile than average (for this exchange).
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
We’ve rounded up stats on some of the most popular wheat stocks, along with information on how these stocks compare and how to invest.